David Greenberg, M.D.

David Greenberg, M.D., is a Professor and Distinguished Teaching Professor in the Department of Internal Medicine at UT Southwestern Medical Center, and a member of its Division of Infectious Diseases and Geographic Medicine. He specializes in transplant infectious diseases, antibiotic-resistant infections, and immunocompromised patients.

Originally from Houston, Texas, Dr. Greenberg holds a bachelor's degree in public health from The Johns Hopkins University in Baltimore, Maryland. He earned his medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston. He then received advanced training in infectious diseases through a fellowship at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.

Certified by the American Board of Internal Medicine in infectious diseases, he joined the UT Southwestern faculty in 2010.

Dr. Greenberg’s research focuses on the development of novel antibacterial therapeutics for multidrug-resistant bacteria. His lab uses peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to block mRNA and prevent translation of target genes. He has received significant grant support for his research, and he holds several patents related to the technology involved.

At UT Southwestern, Dr. Greenberg serves the Director of Microbial Genomics in the Infectious Diseases Division and focuses on utilizing whole-genome sequencing to predict antibiotic resistance. In addition, he co-chairs UTSW’s Biorepository Stewardship Committee and is the Faculty Advisor for the Infectious Diseases Interest Group. He directs several courses for medical students, including one titled Emerging Infectious Diseases and the Microbiome.

Dr. Greenberg has received numerous teaching awards from UT Southwestern. In 2014, he was awarded the Regents’ Outstanding Teacher Award, and in 2020 he was inducted into the Kenneth Shine Academy, the premier health science education academy in the University of Texas system.

He is an active member of the American Society for Microbiology and serves on the Infectious Diseases Society of America’s Antimicrobial Resistance Committee.

University

Johns Hopkins Bloomberg School of Public Health (1995)

Medical School

Baylor College of Medicine (1999)

Residency

Baylor College of Medicine (2002), Internal Medicine

Residency

Baylor College of Medicine (2003), Internal Medicine

Fellowship

National Institutes of Health (2006), Infectious Diseases

• Acinetobacter baumannii
• Antimicrobial development
• Burkholderia cepacia complex
• Gram-negative Bacterial Infections
• Infections in Immunocompromised Hosts

Featured Publications

Inhibition of Pseudomonas aeruginosa by Peptide-conjugated Phosphorodiamidate Morpholino Oligomers.

Howard JJ, Sturge CR, Moustafa DA, Daly SM, Marshall-Batty KR, Felder CF, Zamora D, Yabe-Gill M, Labandeira-Rey M, Bailey SM, Wong M, Goldberg JB, Geller BL, Greenberg DE Antimicrob. Agents Chemother. 2017 Jan

Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo.

Sully EK, Geller BL, Li L, Moody CM, Bailey SM, Moore AL, Wong M, Nordmann P, Daly SM, Sturge CR, Greenberg DE J. Antimicrob. Chemother. 2016 Dec

Sequence-Specific Targeting of Bacterial Resistance Genes Increases Antibiotic Efficacy.

Ayhan DH, Tamer YT, Akbar M, Bailey SM, Wong M, Daly SM, Greenberg DE, Toprak E PLoS Biol. 2016 Sep 14 9 e1002552

Primary osteomyelitis caused by hypervirulent Klebsiella pneumoniae.

Prokesch BC, TeKippe M, Kim J, Raj P, TeKippe EM, Greenberg DE Lancet Infect Dis 2016 Jul

Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex.

Greenberg DE, Marshall-Batty KR, Brinster LR, Zarember KA, Shaw PA, Mellbye BL, Iversen PL, Holland SM, Geller BL J. Infect. Dis. 2010 Jun 201 12 1822-30

Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center.

Greenberg DE, Goldberg JB, Stock F, Murray PR, Holland SM, Lipuma JJ Clin. Infect. Dis. 2009 Jun 48 11 1577-9

Genome sequence analysis of the emerging human pathogenic acetic acid bacterium Granulibacter bethesdensis.

Greenberg DE, Porcella SF, Zelazny AM, Virtaneva K, Sturdevant DE, Kupko JJ, Barbian KD, Babar A, Dorward DW, Holland SM J. Bacteriol. 2007 Dec 189 23 8727-36

A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease.

Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, Miller G, Kleiner DE, Tenorio AR, Brinster L, Dorward DW, Murray PR, Holland SM PLoS Pathog. 2006 Apr 2 4 e28

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens.

Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE, Antimicrob Agents Chemother 2021 Jan 65 2

Discovery and characterization of New Delhi metallo-?-lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae.

Kazi MI, Perry BW, Card DC, Schargel RD, Ali HB, Obuekwe VC, Sapkota M, Kang KN, Pellegrino MW, Greenberg DE, Castoe TA, Boll JM, J Antimicrob Chemother 2020 Oct 75 10 2843-2851

• Kenneth I. Shine, M.D. Academy of Health Science Education
  University of Texas System (2020)
• Regents' Outstanding Teacher Award
  University of Texas System (2014)
• Southwestern Association of Teachers
  UT Southwestern (2014)
• Excellence in Education Award
  UT Southwestern (2013)
• Excellence in Education Award
  UT Southwestern (2012)
• Excellence in Education Award
  UT Southwestern (2011)
• Director's Award
  National Institutes of Health (2007)
• Fellows Award for Research Excellence
  National Institutes of Health (2006)

• American Society for Microbiology
• Infectious Diseases Society of America
• Society for Leukocyte Biology